C22
Conditions
Interventions
Group 1: No study-related examinations or surveys are carried out. Routine clinical practice is recorded retrospectively and the degree of adherence to guidelines is determined.
Sponsors
UKSH Campus Lübeck, Medizinische Klinik I
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis (initial, recurrence or progress) of hepatocellular cancer (Q3/Q4 2024) Diagnosis (initial, recurrence or progress) of biliary tract cancer (Q3/Q4 2024)
Exclusion criteria
Exclusion criteria: Patients with a follow-up time of less than 8 weeks after diagnosis will be excluded (unless they have died within those 8 weeks).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is to investigate the quality of diagnosis and treatment of HCC and BTC in a representative and comprehensive manner throughout Germany. The implementation of diagnostic and therapeutic recommendations in routine clinical practice will be analyzed. | — |
Secondary
| Measure | Time frame |
|---|---|
| Exploratory analysis of patient-specific and health care facility-specific parameters that corre-late with (non)guideline-adherent diagnosis and therapy to provide specific insights for target-ed education. | — |
Countries
Germany
Contacts
Public ContactLaura Holtmann
MMF Research GmbH
Outcome results
None listed